IN8bio Presents Data Update From Induced Pluripotent Stem Cell Platform At The Society For Immunotherapy Of Cancer 38th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
IN8bio, Inc. (NASDAQ:INAB) presented new positive preclinical data from its induced pluripotent stem cell (iPSC) gamma-delta T cell platform at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. The data represents a significant advance in the development of the INB-500 iPSC program towards the development of allogeneic gamma-delta T cell therapies. The company's proprietary process can be scaled for full GMP manufacturing, and the iPSC-derived gamma-delta T cells have shown strong cancer-killing abilities against various solid and liquid cancers.
November 03, 2023 | 4:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio's positive preclinical data from its iPSC gamma-delta T cell platform represents a significant advance in the development of allogeneic gamma-delta T cell therapies. This could potentially boost the company's stock in the short term.
The positive preclinical data presented by IN8bio represents a significant advance in the development of their iPSC gamma-delta T cell therapies. This could potentially lead to increased investor confidence and a boost in the company's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100